Caffeic Acid for Advanced Esophageal Squamous Cell Cancer: A Randomized, Double-blind, and Multicenter Trial in Chinese Patients
Who is this study for? Patients with Esophageal Cancer
What treatments are being studied? Caffeic Acid
Status: Unknown
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer. This study aims to investigate the efficiency and safety of coffeic acid in chinese advanced esophageal squamous cell cancer (ESCC).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Chinese
• esophageal squamous cell cancer
• stage IV or disease recurrence
• chemotherapy, or radiotherapy, or palliative care is going on
Locations
Other Locations
China
The Clinical Medical College, The First Affiliated Hospital of Henan University of Science and Technology
Luoyang
Time Frame
Start Date: 2017-01
Completion Date: 2021-12
Participants
Target number of participants: 300
Treatments
Experimental: CA group
caffeic acid (300mg, tid, po) continue given until progression of disease or death, or patients are unable to bear the side effects
Placebo_comparator: placebo group
the same shape placebo tablets continue given until progression of disease or death, or patients are unable to bear the side effects
Authors
Related Therapeutic Areas
Sponsors
Collaborators: Anyang Tumor Hospital, 150th Hospital of PLA
Leads: The First Affiliated Hospital of Henan University of Science and Technology